Pleural Mesothelioma Treatment Options in 2026

If you or someone you love has been diagnosed with pleural mesothelioma and you're trying to understand what treatment actually looks like in 2026, this page is the place to start.

The treatment landscape has shifted meaningfully in the last five years. Immunotherapy gained FDA approval as a first-line option in 2020, and long-term follow-up data — including five-year CheckMate 743 results — has since confirmed durable responses for a real subset of patients. Surgical patient selection has tightened in the wake of the 2024 MARS2 trial and the post-MARS2 analyses that followed. New combinations of chemotherapy and checkpoint inhibitors are entering standard practice. None of this changes what a pleural mesothelioma diagnosis is, but it changes what the right treatment plan looks like in 2026 versus what it looked like a decade ago.

This page walks through each treatment modality in the depth you'd want before a serious conversation with your oncology team: what surgery actually involves and who's a candidate now, which chemotherapy regimens are first-line and which are alternatives, where immunotherapy fits, what radiation and clinical trials offer, and what each of these costs. If you're looking for the overview of the disease itself, the main pleural mesothelioma page covers diagnosis, staging, and prognosis. If you're focused on financial access to the best care, the treatment and financial help page covers that ground in full.

The treatment landscape today

Pleural mesothelioma is treated using combinations of approaches rather than single drugs or procedures. The phrase for this is multimodal therapy, though the right combination, and whether it includes surgery, varies widely. What varies from patient to patient is which modalities are combined, in what order, and with what intent.

Three factors shape every treatment plan

Three pieces of information determine more about a patient's treatment options than anything else:

• Histological subtype. Whether the tumor is epithelioid, sarcomatoid, or biphasic shapes almost every downstream decision. Epithelioid tumors are more likely to be surgically resectable and tend to respond better to chemotherapy. Non-epithelioid tumors (sarcomatoid and biphasic) gain more from checkpoint immunotherapy relative to chemotherapy, largely because chemotherapy works poorly in them. The cell-type ratio within biphasic tumors matters too; an 80% sarcomatoid biphasic tumor behaves more like sarcomatoid disease, with the same treatment implications.
• Stage at diagnosis. Early-stage disease (TNM Stage I or II) opens the door to surgery as part of a multimodal plan. Locally advanced disease (Stage III) may still permit surgery in selected patients but increasingly favors systemic therapy. Metastatic disease (Stage IV) makes surgery unlikely and shifts the plan toward systemic options aimed at controlling disease and extending life.
• Performance status. A patient's overall fitness and ability to tolerate aggressive treatment (measured on a scale called ECOG, where 0 is fully active and 4 is bedridden) is the third determining factor. Major thoracic surgery, full-course chemotherapy, and checkpoint immunotherapy each demand different things of the body. A 65-year-old with no significant comorbidities has options that a 78-year-old with heart failure and reduced lung function may not.

These three factors interact. A Stage I patient with sarcomatoid histology is generally not a surgical candidate even though the stage alone suggests they might be. A Stage II epithelioid patient with poor performance status may receive a modified chemotherapy regimen rather than the aggressive multimodal plan another patient with the same disease would receive. The treatment conversation should begin with all three facts on the table, not just the stage number.

Treatment sequencing and intent

Beyond the choice of modality, treatment planning involves decisions about timing and goals. Chemotherapy may be given before surgery to shrink tumors (neoadjuvant), after surgery to address residual disease (adjuvant), or as the primary systemic therapy when surgery isn't appropriate. Immunotherapy may be combined with chemotherapy, used alone, or continued as maintenance therapy after an initial response. Radiation, when used, is usually adjunctive rather than primary.

The intent of treatment also matters. For early-stage epithelioid patients at high-volume centers, the goal of aggressive multimodal therapy is meaningful disease control over years. For Stage IV patients or those with sarcomatoid disease, the goal is more often extending life and maintaining quality of life rather than achieving long-term remission. Both are legitimate treatment goals, and being clear about which one applies makes the rest of the conversation easier.

How treatment decisions get made

At high-volume mesothelioma centers, treatment plans are developed in multidisciplinary tumor boards: regular meetings where thoracic surgeons, medical oncologists, radiation oncologists, pathologists, and radiologists review individual cases together. The benefit of that structure is that the patient's full clinical picture, including imaging, pathology, comorbidities, and treatment preferences, is reviewed by specialists with significant mesothelioma experience before a recommendation is made. At community oncology practices that see a handful of mesothelioma cases per year, that level of coordinated review usually isn't available, which is one of several reasons consultation at a specialty center matters even when most day-to-day treatment will be delivered locally.

Surgery for pleural mesothelioma

Surgery has long been a tool against pleural mesothelioma, but 2024 and 2025 produced a new scientific debate about who benefits, under what conditions, and at which centers. Understanding that debate is important because the answer to "should I have an operation?" depends heavily on factors that vary from patient to patient.

The short version: surgery may still benefit carefully selected patients at high-volume centers, with emphasis on selected, but that benefit has not been proven in a randomized trial. A major randomized trial published in 2024 found that surgery provided no benefit and caused harm in a broadly defined patient population. Subsequent analyses have shown that the patients who fared worst in that trial were those who, by current standards, should not have been considered surgical candidates in the first place. Within the surgical arm, patients who met modern selection criteria had substantially better outcomes than those who did not. What that means for any individual patient depends on their specific situation.

Here is what the evidence currently shows.

The two operations: P/D and EPP

There are two main surgical procedures for pleural mesothelioma. They differ substantially in scope, risk, and recovery, and the field has shifted decisively toward one of them.

Pleurectomy/decortication (P/D) is a lung-sparing procedure that removes the pleural lining along the lung and chest wall, along with visible tumor deposits on the diaphragm or pericardium. The lung itself is left in place. P/D is less radical than EPP, carries lower surgical mortality, and allows for faster recovery. In extended P/D, the version tested in MARS2, the surgeon also removes and reconstructs part of the diaphragm and/or pericardium when needed. At experienced centers, it can achieve meaningful tumor cytoreduction while preserving the lung function patients need to tolerate subsequent chemotherapy and immunotherapy. Recovery commonly takes several weeks or longer, with chest-wall pain and reduced stamina sometimes lasting months. Best candidates are early-stage patients with epithelioid tumors, good performance status, no significant lymph node involvement, and preserved cardiopulmonary reserve.

Extrapleural pneumonectomy (EPP) is a more radical procedure that removes the entire affected lung, the pleura, part of the diaphragm, and the pericardium. It achieves more complete cytoreduction in some cases but at substantially higher cost in surgical risk, recovery time, and the lung function the patient permanently loses. EPP has fallen significantly out of favor at most major mesothelioma centers. The field has shifted toward P/D as the preferred approach, with EPP now reserved for rare situations where anatomy or tumor distribution makes P/D insufficient. Recovery is longer, often months, with more intensive rehabilitation.

Both procedures are almost always performed as part of a multimodal plan, combined with chemotherapy and increasingly with immunotherapy. Surgery isn't a standalone treatment for mesothelioma.

What MARS2 found and why it's contested

In 2024, the MARS2 trial published results in Lancet Respiratory Medicine that shook the mesothelioma surgical community. The trial randomized 335 patients: 169 to extended pleurectomy/decortication plus chemotherapy and 166 to chemotherapy alone. The result was clear and unsettling: patients who received surgery had worse survival (median 19.3 months) than those who received chemotherapy alone (median 24.8 months), along with worse quality of life, greater toxicity, and higher costs.¹

For many in the oncology community, MARS2 was confirmation of what prior randomized trials had suggested: that the survival benefit attributed to surgery in mesothelioma may have reflected patient selection bias rather than the operation itself. Patients who undergo surgery tend to be younger, fitter, and have earlier-stage disease; in nonrandomized studies, they naturally do better, though not necessarily because of the surgery itself. The trial's prespecified comparison by cell type found the higher death risk in the surgical arm in epithelioid patients too, the group that had been considered most likely to benefit from an aggressive surgical approach; 86% of trial participants had epithelioid disease.^1,2

If MARS2 were the only data point, the conclusion would be straightforward: don't operate. But it isn't.

What the post-MARS2 analyses found

Within months of MARS2's full publication, a series of analyses identified methodological concerns that complicate a simple "surgery doesn't work" interpretation.^2,3

The most significant challenge came from a post-hoc analysis by Waller et al. (2025), published in Cancers, which examined 79 patients from the surgical arm of MARS2 in detail. Their finding was striking: only 27 of the 79 operated patients they reviewed (34%) met what the authors defined as contemporary selection criteria: Stage I/II epithelioid disease by 9th edition TNM. The patients who did meet those criteria had a median survival of 32 months. Those who didn't had median survival of just 8.5 months. The difference was highly significant (p < 0.0005).³

In other words, MARS2's surgical arm included a large number of patients who by current standards would not be surgical candidates: mainly patients with advanced T3/T4 disease or nodal involvement, plus a small number with non-epithelioid histology and some whose disease was already progressing. Those patients fared poorly, and the patients who met modern criteria did substantially better. Because this comparison is within the surgical arm, without a matched group of similar patients treated without surgery, it cannot prove that surgery helped the better-selected patients; the authors call for another trial.

Other critiques centered on the trial's staging methodology. PET-CT was used in only about 40% of participants, and invasive mediastinal staging was not required. Both tools are now considered standard for preoperative staging at high-volume centers. The 90-day surgical mortality in MARS2 was 9%, a rate that contemporary high-volume programs consider far above their benchmarks.^1–3

That last point is illustrated directly by a 2026 retrospective study from Mount Sinai (Annals of Thoracic Surgery) examining 71 patients who underwent P/D at a high-volume center using modern patient selection with PET-CT staging for every patient; 56 of the 71 had epithelioid tumors, 13 biphasic, and two sarcomatoid. The result was zero in-hospital and 30-day mortality and only 4.2% 90-day mortality, a fraction of MARS2's rate.⁴ The authors attribute the difference to patient selection, modern imaging, and surgical expertise. It is a single-center, nonrandomized series, so it cannot prove that those factors caused the difference, but it raises questions about how far MARS2's results generalize.

Where the field stands now

The current consensus reflected in ASCO guidance, recent review literature, and major mesothelioma centers' practice is that MARS2 has meaningfully changed practice but has not ended mesothelioma surgery.^2,5

A 2025 Journal of Thoracic Oncology perspective (Lim et al.) presented opposing expert views on MARS2, from arguing that mesothelioma should no longer be treated as a surgical disease to arguing that surgery still has a place in selected patients.² The 2025 ASCO guideline update (Kindler et al.) is more prescriptive: surgery should be offered only to highly selected patients at low-morbidity, high-volume centers, ideally within the framework of clinical trials, by multidisciplinary teams with specific mesothelioma expertise.⁵

The practical implications for patients:

• Epithelioid histology, Stage I or II, good performance status, no significant nodal disease: Surgery remains a legitimate option and should be discussed with a mesothelioma surgeon at a high-volume center.
• Non-epithelioid histology (sarcomatoid, or biphasic with significant sarcomatoid component): Surgery is generally not recommended; systemic therapy is the primary approach.
• Advanced stage (III/IV), significant lymph node involvement, or disease that has already progressed: Surgery is generally not recommended, though some presentations need individual assessment.
• Any stage, any histology, at a hospital without specific mesothelioma surgical experience: A consultation at a high-volume center before any surgical decision is strongly advisable.

What surgery can and cannot do

Even in the best candidates, surgery for pleural mesothelioma is cytoreductive rather than curative. The goal is to remove as much visible tumor as possible, reducing the burden on the body and the immune system, relieving symptoms like breathlessness and chest pain, and creating conditions in which chemotherapy and immunotherapy can work more effectively on residual disease. Surgery is part of a multimodal plan, not a standalone treatment, and whether it adds benefit for a particular patient is a case-by-case judgment.

If you've been told you might be a surgical candidate, the most important next step is a consultation with a thoracic surgeon who specializes in mesothelioma at a center that operates on a substantial number of cases per year. The contrast between the Mount Sinai outcomes and the MARS2 outcomes illustrates how much surgical results can vary depending on patient selection, staging rigor, surgical expertise, and center experience.

Chemotherapy

Chemotherapy has been the backbone of pleural mesothelioma treatment for more than two decades, and it remains central to care in 2026, whether used as primary therapy for patients who aren't surgical candidates, as part of a multimodal plan around surgery, or in combination with immunotherapy. The regimens, mechanisms, and supporting evidence are below. Specific drug costs are covered in the consolidated cost section later on this page.

Standard first-line: pemetrexed and cisplatin

The combination of pemetrexed (brand name Alimta) and cisplatin has been the first-line standard of care for pleural mesothelioma since 2003, when the pivotal EMPHACIS Phase III trial demonstrated that patients receiving the combination lived a median of 12.1 months compared to 9.3 months for cisplatin alone, a statistically significant improvement that came with better symptom control and quality of life measures.^6,19 It remains the most thoroughly studied and most widely used chemotherapy approach for this disease.

The two drugs work through complementary mechanisms. Pemetrexed is an antifolate that interferes with the folate-dependent enzymes cancer cells rely on to synthesize DNA and RNA. Without those building blocks, cells can't replicate, and because mesothelioma cells divide more rapidly than most healthy cells, they're particularly vulnerable to this disruption. Pemetrexed also requires vitamin B12 and folic acid supplementation before and during treatment to reduce toxicity to healthy cells; this supplementation is standard and important, not optional. Cisplatin is a platinum-based agent that damages DNA directly, introducing lesions that cancer cells can't repair, which triggers programmed cell death. The combination of the two agents hitting cell replication and DNA integrity simultaneously produces better results than either drug alone.

Treatment is typically delivered in six cycles, administered every three weeks. Response is assessed by imaging between cycles, and the plan is adjusted based on how the tumor is responding and how well the patient is tolerating the regimen.

When cisplatin isn't an option: carboplatin

Not every patient can tolerate cisplatin. Kidney function impairment, significant hearing loss, peripheral neuropathy, or other comorbidities can make cisplatin too risky. In these cases, carboplatin is substituted as the platinum agent. Carboplatin has a more favorable toxicity profile, particularly regarding kidney and nerve effects, though it carries a higher risk of bone marrow suppression.

The pemetrexed-carboplatin combination hasn't been tested in a landmark Phase III trial the way pemetrexed-cisplatin has, but clinical experience and retrospective data support its use as an appropriate alternative for patients who can't safely receive cisplatin. It's widely used in older patients and those with relevant comorbidities, and most major guidelines endorse it as an acceptable first-line option in this population.⁶

Adding bevacizumab: an off-label option for some patients

The MAPS trial (Lancet, 2016) demonstrated that adding bevacizumab, an anti-angiogenic agent that cuts off the tumor's blood supply by blocking vascular endothelial growth factor (VEGF), to pemetrexed and cisplatin improved both progression-free survival and overall survival compared to chemotherapy alone, with median overall survival of 18.8 months versus 16.1 months in the chemotherapy-only arm.^6,20

That's a real and meaningful improvement, but there's an important reality patients should understand. Bevacizumab isn't FDA-approved for pleural mesothelioma in the United States, and it isn't a routine component of standard first-line chemotherapy at most American cancer centers the way it is in parts of Europe, particularly France, where MAPS was conducted. American oncologists may use it off-label in selected patients, but insurance coverage is inconsistent, and its addition significantly increases treatment costs.

If bevacizumab is discussed as part of your treatment plan, it's worth asking your oncologist about the evidence basis, whether it's appropriate for your histology and overall health, and what your insurance is likely to cover. For patients with a valid asbestos claim, documented off-label drug costs can be part of what a recovery addresses.

Alternative regimen: gemcitabine and cisplatin

For patients who can't tolerate pemetrexed, gemcitabine combined with cisplatin (or carboplatin) is the principal alternative. Gemcitabine is a nucleoside analogue that mimics the natural building blocks of DNA and is incorporated into the replication process, where it disrupts copying and triggers cell death. Cancer cells, which replicate more rapidly than healthy tissue, are especially vulnerable. Combined with cisplatin's DNA-damaging mechanism, the two drugs produce complementary cytotoxic effects.

Clinical trial data for gemcitabine-cisplatin in mesothelioma shows response rates of 12% to 48% and median survival ranging from 9.6 to 11.2 months, outcomes competitive with, if not as well-established as, the pemetrexed-cisplatin data.⁶ It's the most commonly used second-line or alternative first-line regimen and is included in major treatment guidelines as an appropriate option for pemetrexed-ineligible patients.

Chemotherapy as part of a multimodal plan

A point worth emphasizing: the survival numbers from chemotherapy trials (the 12.1 months for pemetrexed-cisplatin in EMPHACIS, for example) reflect chemotherapy used as a standalone treatment in trial populations that included patients across all stages and histologies. In practice, chemotherapy is frequently combined with immunotherapy, used before or after surgery, or administered as maintenance therapy following an initial response. Outcomes in those combined-modality settings can be substantially better than what single-agent or doublet-chemotherapy trials show in isolation.

This is why treatment planning at a high-volume mesothelioma center, where physicians are experienced in sequencing and combining modalities, produces meaningfully different results than chemotherapy administered as a standalone treatment at a facility without that expertise.

Immunotherapy

Immunotherapy has fundamentally changed the treatment landscape for pleural mesothelioma. Before 2020, the standard of care for patients with unresectable disease was chemotherapy alone. The FDA approval of nivolumab plus ipilimumab in October 2020 shifted that standard, and ongoing research has continued to produce results that expand options across histological subtypes and treatment settings.⁷ For patients diagnosed today, immunotherapy is a first-line consideration, not an experimental one or a last resort.

How checkpoint immunotherapy works

Mesothelioma tumors, like many cancers, exploit the immune system's own regulatory mechanisms to avoid detection and destruction. They do this partly by expressing proteins, most notably PD-L1, that bind to receptors on immune T-cells and switch them off, sending a "don't attack" signal that prevents the immune system from recognizing the tumor as a threat.

Immune checkpoint inhibitors work by blocking these off-switches. Two molecular targets are most relevant in mesothelioma:

• PD-1 / PD-L1. The PD-1 receptor on T-cells, when bound by PD-L1 on tumor cells, suppresses immune activity. Drugs that block this interaction (anti-PD-1 agents like nivolumab and pembrolizumab) release that suppression and re-activate tumor surveillance.
• CTLA-4. A separate checkpoint protein that regulates T-cell activation earlier in the immune response. Blocking CTLA-4 with ipilimumab increases the overall level of T-cell activity, complementing the PD-1 blockade. The two drugs act on complementary checkpoints.

The landmark trial: CheckMate 743

The CheckMate 743 trial established the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a standard first-line option for unresectable pleural mesothelioma. The results, published in The Lancet in 2021, showed median overall survival of 18.1 months for patients receiving immunotherapy versus 14.1 months for patients receiving chemotherapy, a statistically significant and clinically meaningful improvement.⁸ The FDA approved the combination for unresectable pleural mesothelioma in October 2020, making it only the second FDA-approved systemic drug regimen for this disease after the pemetrexed-cisplatin doublet approved in 2004.

The histology-specific results deserve particular attention. For patients with non-epithelioid histology (sarcomatoid and biphasic), the benefit was dramatic: median survival with immunotherapy was 18.1 months versus 8.8 months with chemotherapy, more than doubling survival in a group that had previously had almost no effective options. The hazard ratio of 0.46 for non-epithelioid patients represents one of the most striking treatment effects documented in mesothelioma research.⁸

For patients with epithelioid histology, the result was more modest: 18.7 months with immunotherapy versus 16.5 months with chemotherapy, a smaller difference that wasn't statistically significant in isolation. That raised questions about whether epithelioid patients benefit from immunotherapy over chemotherapy, which longer follow-up has helped clarify.⁸

Long-term CheckMate 743 data: durability changes the calculation

The updated three-year survival analysis from CheckMate 743, reported by Peters et al. in Annals of Oncology (2022), changed how the trial's results should be interpreted for epithelioid patients specifically, and for any patient considering long-term disease control.⁹

At three years, 23% of patients receiving immunotherapy were still alive, compared to 15% in the chemotherapy arm. The improvement was sustained and present in both histologic subgroups, including a modestly higher three-year survival rate in epithelioid patients, though the subgroup analysis on its own does not settle how large the epithelioid benefit is.

What this means practically: immunotherapy produces a subset of patients who respond deeply and durably, sometimes for years. Chemotherapy produces more uniform but shorter-duration responses. When you look only at median survival, the epithelioid benefit appears marginal. When you look at the right tail of the survival curve, the patients who are still alive at two, three, and four years, the immunotherapy advantage looks more meaningful, including in epithelioid disease. For a patient and their family, the difference between a treatment that moves the median by two months and a treatment that gives a meaningful percentage of patients multi-year disease control is the difference between time being measured in months or in years.

Five-year follow-up, reported in 2026, reinforced this picture: 14% of patients treated with nivolumab plus ipilimumab were alive at five years versus 6% with chemotherapy, with the survival advantage sustained across both histologic subtypes.¹¹

The chemoimmunotherapy triplet: IND.227 / KEYNOTE-483

For patients and oncologists who want to combine the cytoreductive effect of chemotherapy with the immune activation of checkpoint blockade, the IND.227 / KEYNOTE-483 trial provides the most current evidence base. This Phase 2/3 trial evaluated the addition of pembrolizumab (an anti-PD-1 checkpoint inhibitor) to standard pemetrexed plus platinum chemotherapy as first-line treatment.¹² On the strength of that trial, the FDA approved pembrolizumab with pemetrexed and platinum chemotherapy in September 2024 as a first-line option for unresectable advanced or metastatic pleural mesothelioma — the third systemic regimen approved for the disease, after the pemetrexed-cisplatin doublet (2004) and nivolumab-ipilimumab (2020). The triplet regimen achieved:

• Median overall survival of 17.3 months versus 16.1 months for chemotherapy alone
• Response rate of 62% versus 38% as assessed by the study investigators (the FDA's blinded independent review reported 52% versus 29%)
• A hazard ratio of 0.79, representing a 21% reduction in the risk of death¹²

The overall survival improvement was modest, about one month at the median, but the substantially higher response rate means more patients had measurable tumor shrinkage, which can matter when shrinking the tumor quickly is a priority.

Whether the triplet is preferable to the doublet immunotherapy of nivolumab-ipilimumab, or to chemotherapy alone, depends on the individual patient's histology, performance status, and treatment goals. That's a decision best made with a mesothelioma specialist who can weigh the specific tradeoffs. Both approaches are now recognized as legitimate first-line options for different patient profiles.

Immunotherapy and patient selection

Not all mesothelioma patients respond to immunotherapy equally. The current evidence points to several factors that influence the likelihood and durability of response:

• Non-epithelioid patients (sarcomatoid and biphasic with significant sarcomatoid component) gain the most from checkpoint blockade relative to chemotherapy, largely because chemotherapy works poorly in them; PD-L1 levels did not reliably predict who benefited. For these patients, nivolumab-ipilimumab over chemotherapy is supported by the most compelling data, and most major guidelines recommend immunotherapy as the first-line choice.
• Epithelioid patients benefit too, particularly in long-term disease control, though the magnitude of benefit at the median is smaller. The chemotherapy-immunotherapy triplet may be appropriate for patients in whom a high initial response rate is particularly important (for example, those being considered for surgery following neoadjuvant treatment).
• PD-L1 expression is a potential biomarker for immunotherapy response, but it's imperfect. Some PD-L1-negative tumors respond, and some PD-L1-positive tumors don't. It should inform the treatment conversation rather than function as a binary inclusion or exclusion criterion.
• BAP1 loss in the tumor, more common in epithelioid disease, may be associated with longer survival independent of treatment, though its specific predictive value for immunotherapy response remains under investigation.

Current ASCO guidance recommends offering germline (inherited) genetic testing to people with mesothelioma. Tumor profiling is a separate test that can help identify rare actionable alterations or clinical trials; if your treatment center hasn't discussed either, it's worth asking about.⁵

Radiation, emerging therapies, and clinical trials

The treatments covered so far (surgery, chemotherapy, and immunotherapy) make up the core of standard-of-care pleural mesothelioma treatment in 2026. Radiation plays a more limited role, and a substantial pipeline of investigational therapies is in various stages of clinical development. For many patients, the most current standard isn't on this list yet because it's still being studied in clinical trials.

Radiation therapy

Radiation therapy has a limited but meaningful role in pleural mesothelioma care. Unlike many cancers where radiation can be curative, pleural mesothelioma's anatomical spread across the entire chest cavity lining makes delivering curative-intent radiation difficult. The tumor surrounds the lung in a continuous sheet, and the surrounding healthy tissues (lung, heart, esophagus, and spinal cord) can't tolerate the doses that would be needed to eradicate disease across that volume.

Radiation is most commonly used in three settings:

• Palliative symptom relief. Focal external-beam radiation, often given in a short hypofractionated course, can shrink tumor deposits causing pain, breathlessness from airway compression, or other focal symptoms; SBRT is one technique among several rather than the usual approach for every target. The goal isn't disease eradication; it's reducing the tumor burden in a specific location to improve quality of life.
• Post-surgical adjuvant treatment. After EPP, when the lung is gone and the surrounding tissues have shifted, intensity-modulated radiation therapy (IMRT) can be delivered to the post-surgical hemithorax to address microscopic residual disease. IMRT-after-EPP has been used at some centers as part of a trimodal plan (chemotherapy + surgery + radiation). With EPP itself falling out of favor, this approach has become less common. Adjuvant radiation after P/D is more technically challenging because the lung is still in place and isn't standard practice.
• Prevention of seeding along procedure tracts. Some centers have used brief radiation courses to prevent tumor seeding along the tracks of biopsy needles or chest tubes, but randomized trials have not shown a clear benefit, and routine prophylactic tract irradiation is not a standard part of modern mesothelioma care.

For most pleural mesothelioma patients, radiation isn't a primary treatment but a tool for managing specific symptoms or specific post-surgical situations. If radiation is being recommended as part of your treatment plan, it's reasonable to ask about the specific goal and the expected benefit.

Emerging treatment strategies

A substantial pipeline of investigational therapies is in various stages of clinical development for pleural mesothelioma. These aren't standard care in 2026, but several have produced encouraging early results and may become standard care over the next several years. Clinical trial participation is how patients can access these therapies today.

Targeted therapies and molecular profiling. Mesothelioma tumors carry recurring molecular alterations, most notably loss of BAP1, CDKN2A, and NF2. Some of these alterations may create vulnerabilities that targeted drugs can exploit. PARP inhibitors, for example, are being studied in BAP1-deficient mesothelioma based on evidence that BAP1 loss creates a DNA-repair deficiency similar to BRCA mutations in breast and ovarian cancer. EZH2 inhibitors have also been studied in BAP1-deficient tumors. Whether these targeted approaches will produce clinically meaningful benefit remains under investigation. Tumor profiling can help identify patients who might qualify for targeted approaches or specific clinical trials.

Arginine depletion (pegargiminase). In the ATOMIC-Meso trial of 249 patients with untreated non-epithelioid pleural mesothelioma, adding pegargiminase (ADI-PEG 20), a drug that depletes the amino acid arginine, to platinum-pemetrexed chemotherapy improved median overall survival from 7.7 to 9.3 months, with more severe side effects (28.8 versus 16.9 percent).²¹ ASCO's 2025 guideline says it may be offered to non-epithelioid patients who have had no prior systemic therapy and are not candidates for immunotherapy, a conditional recommendation.⁵ It is not FDA-approved: its maker withdrew its U.S. application in May 2026, citing business strategy, and it is not commercially available in the United States.²²

Mesothelin-directed therapies. Mesothelin is a protein highly expressed on mesothelioma cells but largely absent from healthy tissues, making it an attractive therapeutic target. Antibody-drug conjugates that deliver cytotoxic agents directly to mesothelin-expressing tumor cells have been studied; one, anetumab ravtansine, did not meet its main goal in a randomized pleural mesothelioma trial. Mesothelin-targeted approaches are being studied alone and in combination with immunotherapy.

CAR T-cell therapy. Chimeric antigen receptor T-cell therapy, which has produced remarkable results in certain blood cancers, is being adapted for solid tumors including pleural mesothelioma. Early-phase trials of mesothelin-directed CAR T-cells have shown both promise and significant safety challenges. CAR T for solid tumors is genuinely at the research frontier, and patients should understand the realistic timeline: meaningful availability outside clinical trials is likely years away rather than months.

Newer immunotherapy combinations. Beyond CheckMate 743, multiple combinations are being studied: durvalumab combined with chemotherapy (DREAM and PrE0505 trials), atezolizumab combined with bevacizumab and chemotherapy (the BEAT-meso trial), and various combinations of PD-1/PD-L1 inhibitors with other immune-modulating agents. Some of these combinations may produce results that change the standard of care over the next several years.

Accessing clinical trials

Clinical trial participation is one of the most underutilized tools available to mesothelioma patients. Trials provide access to therapies that aren't yet broadly available, often with the sponsor supplying the investigational treatment (routine-care cost sharing, travel, and uncovered services may still apply), and frequently include intensive monitoring and care from specialists with deep mesothelioma experience.

The National Library of Medicine maintains ClinicalTrials.gov, a searchable database of clinical studies that can be filtered by disease, location, and eligibility criteria; the National Cancer Institute also maintains cancer-specific trial-search resources. The challenge is that most patients (and many community oncologists) don't routinely search this resource, and the eligibility criteria can be difficult to interpret without specialist help.

The more effective path for most patients is to consult with a mesothelioma specialist at a high-volume academic center, where active trials are routinely incorporated into the treatment conversation. Specialists at NCI-Designated Cancer Centers and major mesothelioma programs typically know which trials are open, whether a particular patient is a candidate, and what the trial would involve practically. Some patients receive their entire care through trial participation; others receive standard treatment supplemented by a trial in a specific phase.

A few practical points worth knowing:

• Most plans must cover routine care costs in qualifying trials (standard imaging, hospitalization, supportive care), while the trial usually covers the experimental drug and research-only testing; coverage varies by plan and is less certain out of network, so confirm it with the study team and insurer.
• Travel and lodging for trial participation at distant centers can sometimes be covered by patient assistance programs, hospital social work, or asbestos settlement funds.
• Trial participation doesn't preclude later standard treatment if the trial therapy doesn't work; in many cases, trial enrollment provides additional information that informs subsequent decisions.

If you're being treated at a center that hasn't discussed clinical trials with you, asking about trial options, either at your current center or via referral to a higher-volume program, is a reasonable next step.

What pleural mesothelioma treatment costs

Pleural mesothelioma treatment is among the most expensive cancer care in modern medicine, but the word "cost" hides several different numbers, and they aren't interchangeable. A hospital's billed charge is rarely what anyone pays. An insurer's negotiated allowed amount is lower. A Medicare payment limit is set by formula. And the patient's out-of-pocket responsibility is different again, shaped by the specific plan, the network, and how long treatment continues. The tables below keep those concepts separate, because the most common mistake families and websites make is treating a drug's acquisition cost as if it were the cost of treatment, or treating a billed charge as if it were the bill the family will actually face.

A second distinction matters just as much. The cost of the drugs is not the cost of the care. Generic chemotherapy drugs are now inexpensive to acquire, but the chemotherapy episode (infusion visits, hydration, anti-nausea drugs, lab monitoring, imaging, and management of complications) costs far more than the drugs in the bag. Modern immunotherapy reverses that ratio: there, the drug itself is the dominant cost. We show both layers below.

Drug-only estimates below use 2026 Medicare Part B Average Sales Price (ASP) payment-limit data, which is public and updated quarterly; Medicare pays most separately payable Part B drugs at ASP plus 6%.¹⁴ Total-care figures use real-world mesothelioma claims data and should be read as planning ranges, not guarantees. All figures vary by insurance, region, treatment center, complications, and treatment duration.

What the drugs cost (drug-only estimates)

The figures below are drug-only Medicare payment-limit estimates for an illustrative adult patient (about 1.8 m² body-surface area, about 75 kg) receiving six 21-day cycles, priced from 2026 Medicare ASP payment limits.¹⁴ They do not include infusion administration, hydration, anti-nausea drugs, growth factors, lab monitoring, imaging, physician visits, hospitalization, or complications, all of which are covered separately below.

Chemotherapy regimens (drug-only ASP payment-limit estimate, six-cycle course):

Regimen	Approximate drug-only cost (ASP payment limit)
Pemetrexed + cisplatin (standard first-line)	≈ $2,400
Pemetrexed + carboplatin (cisplatin alternative)	≈ $2,400 (carboplatin dosed by kidney function; illustrative)
Gemcitabine + cisplatin (alternative regimen)	≈ $500–$800
Add bevacizumab to chemotherapy (off-label)	Adds ≈ $50,000 (six-cycle induction; maintenance bevacizumab would add more)

Two points are easy to miss here. First, generic pemetrexed (the former brand Alimta) is now inexpensive; the high five-figure "chemotherapy drug cost" figures still circulating online reflect branded pricing from before generic entry. The generic chemotherapy backbone for mesothelioma is a few thousand dollars to acquire. Second, when bevacizumab is added, it, not the chemotherapy, is the cost driver, and because bevacizumab is not FDA-approved for pleural mesothelioma in the United States, that added cost is also the part most likely to meet insurance resistance.

Immunotherapy regimens (drug-only ASP payment-limit estimate, first-year):

Regimen	Approximate first-year drug cost
Single-agent pembrolizumab (not FDA-approved on its own for mesothelioma; off-label)	≈ $210,000
Pembrolizumab + pemetrexed/platinum chemotherapy	≈ $215,000
Nivolumab + ipilimumab (CheckMate 743 regimen)	≈ $290,000–$330,000

These figures are driven almost entirely by the immunotherapy drugs themselves. The FDA-approved mesothelioma dose for the nivolumab/ipilimumab combination is nivolumab 360 mg every three weeks plus ipilimumab 1 mg/kg every six weeks, continued until progression, unacceptable toxicity, or up to two years.¹⁷ Pembrolizumab is dosed at 200 mg every three weeks or 400 mg every six weeks; Merck's 2026 list price is roughly $12,000 per 200 mg dose, which is consistent with the annual estimates above.¹⁶ One U.S. cost-effectiveness model estimated a total cost of about $292,000 for the nivolumab/ipilimumab strategy over a ten-year horizon, which is a modeled total rather than an annual price.¹⁸ Unlike chemotherapy, these regimens continue for many months, so the longer a patient responds, the higher the cumulative drug cost, a welcome problem clinically but a real one financially.

What the care costs (real-world benchmarks)

Drug acquisition is only one line on the bill. The most useful public anchor for the total medical-care burden comes from a SEER-Medicare analysis of older adults with malignant pleural mesothelioma, which found mean all-cause health care costs of about $11,432 per patient per month and a median overall survival of 16.3 months.¹³ Translated into planning terms, that is roughly $69,000 over a six-month first-line episode and roughly $137,000 over a year.

One caveat is important: that benchmark comes from a population treated largely before immunotherapy became standard, so it captures baseline medical care well but does not include the cost of modern checkpoint-inhibitor drugs.¹³ A rough way to estimate a modern course is to start from that benchmark and add the immunotherapy drug cost. That is an illustration, not a measured total: the benchmark already includes the chemotherapy drugs those patients received, so simply adding immunotherapy can overstate the total somewhat.

First-year scenario	Planning estimate	What it includes / excludes
Chemotherapy-based first-line, no surgery	≈ $70,000–$140,000 over 6–12 months	Real-world all-cause care; generic chemo drug acquisition is small by comparison13
Pembrolizumab + chemotherapy	≈ $285,000–$355,000 first year	≈ $215,000 drug cost plus baseline care13,16
Nivolumab + ipilimumab	≈ $360,000–$470,000 first year	≈ $290,000–$330,000 drug cost plus baseline care13,14
Surgery + systemic therapy	Systemic-therapy scenario plus a surgical episode	See surgery note below; we don't publish a single national surgery price
Continued immunotherapy in long responders	Add ≈ $210,000–$330,000 per additional year while treatment continues	Drug acquisition only; most regimens cap at two years if tolerated16,17

Surgery and hospitalization

Surgical costs for pleural mesothelioma vary too widely to reduce to a reliable national figure, and we'd be skeptical of any site that gives you one. There is no strong, modern, U.S.-specific dataset that cleanly separates pleurectomy/decortication from extrapleural pneumonectomy with dependable allowed amounts. What can be said honestly is more useful than false precision:

Surgical cost component	What families should understand
The operation (P/D or EPP)	Cost varies substantially by hospital, insurer, procedure, complications, ICU use, and length of stay. Ask the treating center and insurer for a written estimate using the planned procedure codes before surgery.
Hospitalization and complications	Hospitalization is the largest single driver. Older U.S. data put the mean mesothelioma hospitalization at more than $24,000, and a complex operation or complications can raise the total well beyond that.10 EPP, with its longer stay and higher complication rate, costs more than the now-preferred P/D.
Out-of-network specialty care	The decisive financial question is usually not the surgeon's billed charge but whether the surgeon, hospital, anesthesia group, pathology, imaging, and follow-up are all in network. A single out-of-network component can dwarf the rest.

Supportive and additional care

Beyond the primary treatment, mesothelioma care involves ongoing costs that accumulate over months and years. The figures below are illustrative; your insurer's estimate or the Medicare Procedure Price Lookup will be more accurate for your situation.

• Diagnostic imaging: CT of the chest is typically repeated every two to three months during active treatment or surveillance; PET/CT is higher-cost and used more selectively for staging or suspected progression.
• Laboratory monitoring: Regular blood work accompanies every chemotherapy and immunotherapy cycle.
• Pleural fluid management: Thoracentesis or an indwelling tunneled catheter, highly variable by site of service and complications.
• Infusion services and supportive drugs: Administration fees, anti-nausea drugs, hydration, and growth factors. These are a large part of why the chemotherapy episode costs far more than the chemotherapy drugs.
• Genetic and molecular testing: Tumor profiling, increasingly recommended, when not fully covered by insurance.

Insurance, Medicare, and what's left over

Insurance covers a large share of these costs, but the structure of modern coverage leaves meaningful amounts out of pocket. How a drug is covered depends on whether it is billed under Medicare Part B or Part D: most infused chemotherapy and immunotherapy is handled under Part B, while many oral supportive medications fall under Part D.

For 2026, Medicare Part D has a redesigned benefit with a $2,100 annual out-of-pocket cap, after which covered Part D drugs cost the enrollee nothing for the rest of the year; the older "coverage gap" (the donut hole) has been eliminated.¹⁵ That cap is real relief for oral medications, but it does not eliminate cost-sharing for Part B infusions, out-of-network services, travel and lodging, or non-covered items, which for mesothelioma patients are often the larger expenses. A patient with good coverage can still face tens of thousands of dollars a year once coinsurance on Part B infusions, out-of-network charges, and travel are added up.

Beyond direct medical costs are the indirect burdens that often exceed the medical bills: income lost by the patient and by caregiving family members, travel and lodging for specialty-center care, home modifications, and the longer-term effect on a family's financial stability.

Where treatment costs and legal recovery connect

For many families, the cost picture changes substantially once legal recovery is part of the planning. Where a valid claim exists, asbestos bankruptcy trust claims and lawsuits against the companies responsible for the exposure can help with gaps insurance doesn't reach, though recovery, amount, and timing are never guaranteed: out-of-pocket costs for FDA-approved treatment, off-label drugs like bevacizumab, clinical-trial travel, consultations and care at distant specialty centers, and the income lost during months or years of treatment.

For broader information on how mesothelioma treatment is paid for, including insurance, federal benefits, charitable assistance, and what to expect from the financial side, see our Getting Treatment and Financial Help page.

How one family paid for this care

This continues the composite example from our main pleural mesothelioma page and follows the same treatment journey. It's illustrative, not a real client.

Daniel is the 66-year-old Navy veteran whose Stage II epithelioid pleural mesothelioma we followed on that page. Here the question is narrower: how his family actually paid for the care described above.

His local oncologist first offered chemotherapy close to home. The plan Daniel chose with a high-volume mesothelioma program, after a frank discussion of the MARS2 results, was lung-sparing surgery (pleurectomy/decortication, which removes the pleural lining but leaves the lung in place) followed by chemotherapy. But it came with obstacles that had nothing to do with medicine. The specialty center was a state away, so the workup and the operation meant repeated travel and lodging. And it was out of network for Daniel's plan.

None of those are medical problems, and all of them are the kind a legal recovery is built to solve. While treatment moved forward, Daniel's claims moved alongside it: trust claims, a lawsuit, and VA benefits tied to his service. Where the written agreement and applicable law permitted it, the firm advanced the travel and lodging up front, so getting to the right surgeon didn't wait on a settlement. The out-of-network costs became part of what the claims sought to recover. Daniel's wife Karen cut back her hours to be with him through the surgery and the infusions that followed, and that lost income was folded into the claim rather than left to the family.

Recoveries aren't always that large or that quick; trust payments are often a fraction of a claim's scheduled value, and lawsuits take longer. The point isn't the specific dollars, it's the sequence. The medical decisions got made on medical grounds, because the cost question was being handled on a separate track. For most families we work with, that's the whole value of calling early: it lets the oncology team decide the medicine, instead of the insurance company deciding it by default.

This example is general. Every case depends on the diagnosis, the treatment plan, the family situation, the available evidence, and applicable law.

References

1. Lim E, Waller D, Lau K, et al; MARS 2 Investigators. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3, open-label, randomised controlled trial. The Lancet Respiratory Medicine. 2024;12(6):457–466. doi:10.1016/S2213-2600(24)00119-X

2. Lim E, Opitz I, Woodard G, et al. A Perspective on the MARS2 Trial. Journal of Thoracic Oncology. 2025;20(3):262–272. doi:10.1016/j.jtho.2024.12.014

3. Waller D, Bilancia R, Ventura L, Tenconi S, Socci L, Bille A. Why the MARS2 Trial Does Not Mean the End of All Mesothelioma Surgery. Cancers. 2025;17(5):724. doi:10.3390/cancers17050724

4. Gulati S, Wolf A, Mehrotra-Varma J, Tuminello S, Taioli E, Flores R. Disaster on MARS2? Lessons Learned from Modern-Day Outcomes of Surgery for Pleural Mesothelioma. The Annals of Thoracic Surgery. 2026. doi:10.1016/j.athoracsur.2026.01.025

5. Kindler HL, Ismaila N, Bazhenova L, et al. Treatment of Pleural Mesothelioma: ASCO Guideline Update. Journal of Clinical Oncology. 2025;43(8):1006–1038. doi:10.1200/JCO-24-02425

6. Imai H. Current drug therapy for pleural mesothelioma. Respiratory Investigation. 2025;63(2):200–209. doi:10.1016/j.resinv.2024.12.017

7. Chiec L, Bruno DS. Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies. International Journal of Molecular Sciences. 2024;25(19):10861. doi:10.3390/ijms251910861

8. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet. 2021;397(10272):375–386. doi:10.1016/S0140-6736(20)32714-8

9. Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Annals of Oncology. 2022;33(5):488–499. doi:10.1016/j.annonc.2022.01.074

10. Borrelli EP, Babcock Z, Kogut SJ. Costs of medical care for mesothelioma. Rare Tumors. 2019;11:2036361319863498. doi:10.1177/2036361319863498

11. Scherpereel A, Baas P, Nowak AK, et al. Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. Journal of Clinical Oncology. 2026;44(9):742–749. doi:10.1200/JCO-25-01328

12. Chu Q, Perrone F, Greillier L, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France (IND.227/KEYNOTE-483): a phase 3, open-label, randomised controlled trial. The Lancet. 2023;402(10419):2295–2306. doi:10.1016/S0140-6736(23)01613-6

13. Aggarwal H, Arunachalam A, Min J, et al. Treatment Patterns, Clinical Outcomes, Health Care Resource Use, and Costs in Older Adults with Malignant Pleural Mesothelioma in the United States, 2007–2020. Advances in Therapy. 2026;43:1290–1307. doi:10.1007/s12325-025-03478-z

14. Centers for Medicare & Medicaid Services. Medicare Part B Drug Average Sales Price (ASP) methodology (payment at ASP plus 6%) and quarterly Pricing Files; April 2026 ASP Pricing File (final), payment limits effective April 1–June 30, 2026.

15. Centers for Medicare & Medicaid Services. Medicare Part D benefit redesign, calendar year 2026 ($2,100 annual out-of-pocket cap; coverage gap eliminated).

16. Merck & Co., Inc. KEYTRUDA (pembrolizumab) list price information, current as of March 2026.

17. Bristol Myers Squibb. OPDIVO (nivolumab) and YERVOY (ipilimumab) U.S. Prescribing Information. Malignant pleural mesothelioma dosing: nivolumab 360 mg every 3 weeks with ipilimumab 1 mg/kg every 6 weeks, up to 2 years.

18. Ye Z, Tang Z, Xu Z, Zhou Q, Li H. Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma. Frontiers in Public Health. 2022;10:947375. doi:10.3389/fpubh.2022.947375

19. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology. 2003;21(14):2636–2644. doi:10.1200/JCO.2003.11.136

20. Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. The Lancet. 2016;387(10026):1405–1414. doi:10.1016/S0140-6736(15)01238-6

21. Szlosarek PW, Creelan BC, Sarkodie T, et al. Pegargiminase plus first-line chemotherapy in patients with nonepithelioid pleural mesothelioma: the ATOMIC-Meso randomized clinical trial. JAMA Oncol. 2024;10(4):475-483. doi:10.1001/jamaoncol.2023.6789.

22. Central News Agency (Taiwan). 北極星藥業撤惡性間皮瘤藥證申請 調整美子公司人力 [Polaris Pharmaceuticals withdraws malignant mesothelioma drug license application]. May 25, 2026. Accessed October 29, 2026. https://www.cna.com.tw/news/afe/202605250314.aspx